FDA Trending News

Regulatory Update Eliminates REMS Program for Caprelsa (vandetanib)

Feb 1, 2026

The U.S. Food and Drug Administration today removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Genzyme Corporation (now Sanofi).

The FDA first approved Caprelsa in 2011 to treat medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At the time, a REMS program was required to ensure appropriate heart rhythm monitoring and safe use. After over more than a decade of oversight, REMS assessments reported no cases of Torsades de pointes or unexplained sudden deaths among U.S. patients taking Caprelsa. Clinical data also showed no concerning patterns of heart rhythm problems.

“Cancer specialists now have adequate knowledge about managing the heart rhythm related risks of this medication,” said Richard Pazdur, M.D., FDA Oncology Center of Excellence Director. “Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals.”

Caprelsa will remain available with the same prescribing information, but health care providers will no longer need special certification or extra monitoring beyond standard clinical care.

A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The safety requirements for Caprelsa included mandatory training for health care providers and monitoring of patients.

Contact Information:

  • Health care providers, pharmacies, and patients with questions may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov.
  • Adverse events, medication errors, or quality problems with Caprelsa should be reported to FDA’s MedWatch Adverse Event Reporting program.
  • FDA’s top priority is patient safety, and the agency will continue to monitor the safety of this medication.

Source:

U.S. Food and Drug Administration. FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib) [Internet]. Silver Spring (MD): FDA; 2025 Sep 25 [cited 2025 Dec 11]. Available from: https://www.fda.gov/news-events/press-announcements/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib

Reported by

Reviewed by

You May Also Like

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

,

Muscle weakness is one of the biggest challenges of aging. As people get older, they naturally lose muscle strength and muscle mass, a condition known as sarcopenia. This can make everyday activities like climbing stairs, carrying groceries, or getting up from a chair much more difficult. While exercise and good nutrition remain the best ways to slow muscle loss, researchers are searching for new treatments that target the underlying causes of age-related muscle weakness.

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

, ,

Many people take glucosamine supplements every day to help support their joints. It has been used for years and is one of the most popular supplements for osteoarthritis. However, a new study is raising questions about whether glucosamine could affect brain health in people with Alzheimer’s disease or mild cognitive impairment.

The Facts on Tampons and Tampon Safety

The Facts on Tampons and Tampon Safety

,

Tampons are absorbent products that you insert into your vagina to soak up menstrual flow during your period. Tampons come in different absorbency levels — like light, regular, and super — so you can pick the right one for your flow. Some have a plastic or cardboard applicator to help with insertion, and others are inserted with your finger.